CD8A and breast carcinoma: A study by Kim et al., showed that infection with VSVΔM51 promotes T-cell recruitment while SMAC mimetic LCL161 treatment aids in rejuvenating exhausted tumor-infiltrating CD8+ T-cells, leading to CD8+ T-cell mediated tumor control in in vivo breast cancer models (87).